CONSULTING AGREEMENTConsulting Agreement • September 25th, 2020 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (the “Agreement”), effective as of the Effective Date (as defined herein), is entered into between Karyopharm Therapeutics Inc. (the “Company”) and Christopher B. Primiano (the “Consultant”). The Consultant and the Company are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
TRANSITION AGREEMENTTransition Agreement • September 25th, 2020 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This Transition Agreement (the “Agreement”) is made as of September 25, 2020 (“the Agreement Effective Date”) by and between Karyopharm Therapeutics Inc. (the “Company”) and Christopher B. Primiano (“Executive”) (together, the “Parties”). Capitalized terms used but not defined herein have the meanings set forth in the 2014 Offer Letter by and between Executive and the Company, as most recently amended on August 31, 2020 (the “Offer Letter”).
